With the introduction of endocrine therapy, the prognosis of early-stage oestrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2−) BC, which comprises approximately 40% of BC4, has improved5 but in about 20% of the cases the decease can still recur post-treatment6. Here, ERBB2 is linked to breast cancer.